| Document and Entity Information - shares | 9 Months Ended | |
| Sep. 30, 2015 | Nov. 12, 2015 | |
| Document and Entity Information | ||
| Entity Registrant Name | OphthaliX, Inc. | |
| Entity Central Index Key | 1,218,683 | |
| Amendment Flag | false | |
| Current Fiscal Year End Date | --12-31 | |
| Document Type | 10-Q | |
| Document Period End Date | Sep. 30, 2015 | |
| Document Fiscal Year Focus | 2,015 | |
| Document Fiscal Period Focus | Q3 | |
| Entity Filer Category | Smaller Reporting Company | |
| Entity Common Stock, Shares Outstanding | 10,441,251 |
| Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Sep. 30, 2015 | Dec. 31, 2014 | |
| CURRENT ASSETS: | |||
| Cash and cash equivalents | $ 14 | $ 9 | |
| Investment in Parent Company | 962 | 794 | |
| Other accounts receivable | 150 | 209 | |
| Total current assets | 1,126 | 1,012 | |
| PROPERTY AND EQUIPMENT, NET | 3 | 1 | |
| Total assets | 1,129 | 1,013 | |
| CURRENT LIABILITIES: | |||
| Related company | 3,304 | 2,457 | |
| Other accounts payable and accrued expenses | 209 | 246 | |
| Total current liabilities | $ 3,513 | $ 2,703 | |
| NON-CURRENT LIABILITIES: | |||
| Derivative related to Service Agreement | [1] | ||
| Share capital | |||
| Preferred Stock - Authorized : 1,000,000 shares at September 30, 2015 and December 31, 2014, respectively; Issued and Outstanding: 0 shares at September 30, 2015 and December 31, 2014 | |||
| Common Stock of $ 0.001 par value - Authorized: 100,000,000 shares at September 30, 2015 and December 31, 2014, respectively; Issued and Outstanding: 10,441,251 shares at September 30, 2015 and December 31, 2014, respectively | $ 10 | $ 10 | |
| Additional Paid-in capital | 5,513 | 5,494 | |
| Accumulated other comprehensive income | 270 | 102 | |
| Accumulated deficit | (8,177) | (7,296) | |
| Total stockholders' deficiency | (2,384) | (1,690) | |
| Total liabilities and stockholders' deficiency | $ 1,129 | $ 1,013 | |
| [1] | Represents an amount lower than $1 | ||
| Condensed Consolidated Balance Sheets (Parentheticals) - $ / shares | Sep. 30, 2015 | Dec. 31, 2014 |
| Statement of Financial Position [Abstract] | ||
| Preferred Stock, shares authorized | 1,000,000 | 1,000,000 |
| Preferred Stock, shares issued | 0 | 0 |
| Preferred Stock, shares outstanding | 0 | 0 |
| Common Stock, par value | $ 0.001 | $ 0.001 |
| Common Stock, shares authorized | 100,000,000 | 100,000,000 |
| Common stock, shares issued | 10,441,251 | 10,441,251 |
| Common Stock, shares outstanding | 10,441,251 | 10,441,251 |
| Condensed Consolidated Statements of Comprehensive Loss (Income) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | 12 Months Ended | ||
| Sep. 30, 2015 | Sep. 30, 2014 | Sep. 30, 2015 | Sep. 30, 2014 | Dec. 31, 2014 | |
| Operating expenses: | |||||
| Research and development | $ 247 | $ 169 | $ 550 | $ 509 | $ 721 |
| General and administrative | 85 | 109 | 270 | 292 | 425 |
| Total operating expenses | 332 | 278 | 820 | 801 | 1,146 |
| Financial expenses, net | 21 | 14 | 61 | 33 | 49 |
| Net loss | $ 353 | $ 292 | $ 881 | $ 834 | $ 1,195 |
| Net loss per share: | |||||
| Basic and diluted loss per share | $ 0.03 | $ 0.03 | $ 0.08 | $ 0.08 | $ 0.11 |
| Weighted average number of Common Stocks used in computing basic and diluted net loss per share | 10,441,251 | 10,441,251 | 10,441,251 | 10,441,251 | 10,441,251 |
| Available-for-sale investments: | |||||
| Changes in net unrealized loss (income) | $ (462) | $ 46 | $ (168) | $ 419 | $ 381 |
| Comprehensive loss (income) | $ (109) | $ 338 | $ 713 | $ 1,253 | $ 1,576 |
| Condensed Consolidated Statements of Changes in Stockholders' Equity Deficiency - USD ($) $ in Thousands | Total | Shares of Common Stock | Additional paid-in capital | Accumulated deficit | Accumulated other comprehensive income |
| Beginning Balance at Dec. 31, 2013 | $ (139) | $ 10 | $ 5,469 | $ (6,101) | $ 483 |
| Beginning Balance, Shares at Dec. 31, 2013 | 10,441,251 | ||||
| Stock based compensation | 12 | 12 | |||
| Unrealized gain from investment in Parent company | (419) | (419) | |||
| Net loss | (834) | (834) | |||
| Ending Balance at Sep. 30, 2014 | (1,380) | $ 10 | 5,481 | (6,935) | 64 |
| Ending Balance, Shares at Sep. 30, 2014 | 10,441,251 | ||||
| Beginning Balance at Dec. 31, 2013 | (139) | $ 10 | 5,469 | (6,101) | 483 |
| Beginning Balance, Shares at Dec. 31, 2013 | 10,441,251 | ||||
| Stock based compensation | 25 | ||||
| Net loss | (1,195) | ||||
| Ending Balance at Dec. 31, 2014 | (1,690) | $ 10 | 5,494 | (7,296) | 102 |
| Ending Balance, Shares at Dec. 31, 2014 | 10,441,251 | ||||
| Stock based compensation | 19 | 19 | |||
| Unrealized gain from investment in Parent company | 168 | 168 | |||
| Net loss | (881) | (881) | |||
| Ending Balance at Sep. 30, 2015 | $ (2,384) | $ 10 | $ 5,513 | $ (8,177) | $ 270 |
| Ending Balance, Shares at Sep. 30, 2015 | 10,441,251 |
| Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands | 9 Months Ended | 12 Months Ended | ||
| Sep. 30, 2015 | Sep. 30, 2014 | Dec. 31, 2014 | ||
| Cash flows from operating activities: | ||||
| Net loss | $ (881) | $ (834) | $ (1,195) | |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||
| Decrease (increase) in other accounts receivable | 59 | (189) | ||
| Decrease in other account payables and accrued expenses | (37) | $ (62) | (17) | |
| Increase in balance with Related company | 847 | $ 524 | $ 970 | |
| Depreciation | $ 1 | [1] | ||
| Changes in fair value of the derivative related to service agreement | $ (6) | $ (7) | ||
| Stock based compensation | $ 19 | 12 | 25 | |
| Net cash provided by (used in) operating activities | 8 | $ (366) | $ (413) | |
| Cash flows from investing activities: | ||||
| Acquisition of fixed assets | (3) | |||
| Net cash used in investing activities | (3) | |||
| Change in cash and cash equivalents | 5 | $ (366) | $ (413) | |
| Cash and cash equivalents at the beginning of the period | 9 | 422 | 422 | |
| Cash and cash equivalents at the end of the period | $ 14 | $ 56 | $ 9 | |
| [1] | Represents an amount lower than $1 | |||
| General | 9 Months Ended |
| Sep. 30, 2015 | |
| General [Abstract] | |
| GENERAL | NOTE 1:- GENERAL a. OphthaliX Inc. (the "Company" or "OphthaliX"), originally incorporated in the State of Nevada on December 10, 1999 under the name Bridge Capital.com Inc., was a nominally capitalized corporation that did not commence its operations until it changed its name to Denali Concrete Management Inc. ("Denali"), in March 2001. Denali was a concrete placement company specializing in providing concrete improvements in the road construction industry. Denali operated primarily in Anchorage, Alaska, placing curb and gutter, sidewalks and retaining walls for state, municipal and military projects. In December 2005, the Company ceased its principal business operations and focused its efforts on seeking a business opportunity, becoming a public shell company in the U.S. Eye-Fite Ltd. ("Eye-Fite" or the "Subsidiary") was founded on June 27, 2011 in contemplation of the execution of a transaction between Can-Fite BioPharma Ltd. (the "Parent company" or "Can-Fite"), a public company in Israel and U.S, and the Company, as further detailed in Note 1b below. The Company and its Subsidiary conduct research and development activities using an exclusive worldwide license for CF101, a synthetic A3 adenosine receptor, or A3AR, agonist (known generically as IB-MECA) solely for the field of ophthalmic diseases after the consummation of the transaction. See also Note 1b2. Following the transaction, Denali changed its name to OphthaliX Inc. and also changed its corporate domicile from Nevada to Delaware. b. Reverse Recapitalization and related arrangements: 1. Recapitalization: On November 21, 2011 (the "Closing Date"), Can-Fite purchased 8,000,000 shares of the Company’s common stock, par value $0.001 per share in exchange for all of the issued and outstanding ordinary shares of Eyefite pursuant to the terms of a stock purchase agreement (the “Purchase Agreement”). As a result, Eyefite became a wholly-owned subsidiary of the Company and Can-Fite became its majority stockholder and a parent. Also on November 21, 2011, the Company issued a warrant to Can-Fite by which Can-Fite has the right, until the earlier of (a) the November 21, 2016 and (b) the closing of the acquisition of the Company by another entity, resulting in the exchange of the Company’s outstanding common shares such that its stockholders prior to such transaction own, directly or indirectly, less than 50% of the voting power of the surviving entity, to convert its right to the Additional Payment (as defined below) into 480,022 shares of Common Stock (subject to adjustment in certain circumstances). The per share exercise price for the shares is $5.148. The Company also received 714,922 ordinary shares in Can-Fite, representing approximately 7% of Can-Fite's issued and outstanding share capital as of the Closing Date. On June 17, 2013, the Company sold 268,095 Can-Fite ordinary shares for a total consideration of $511. As of September 30, 2015, the Company holds 446,827 Can-Fite ordinary shares, representing approximately 1.6% of Can-Fite's outstanding share capital. In contemplation of the recapitalization transaction, it was agreed that for every four shares of Common Stock purchased by the New Investors and Can-Fite, they received nine warrants to acquire two shares of Common Stock of the Company. The exercise price of such warrants is $7.74 per share of Common Stock. The warrants are exercisable for a period of five years from the date of grant. The warrants do not contain nonstandard anti-dilution provisions (see also Note 6b to the consolidated financial statements as of December 31, 2014). The transaction was accounted for as a reverse recapitalization which is outside the scope ASC 805, Business Combinations. Under reverse capitalization accounting, EyeFite is considered the acquirer for accounting and financial reporting purposes, and acquired the assets and assumed the liabilities of the Company. Assets acquired and liabilities assumed are reported at their historical amounts. Consequently, the condensed consolidated financial statements of the Company reflect the operations of the acquirer for accounting purposes together with a deemed issuance of shares, equivalent to the shares held by the former shareholders of the legal acquirer and a recapitalization of the equity of the accounting acquirer. These condensed consolidated financial statements include the accounts of the Company since the effective date of the reverse capitalization and the accounts of EyeFite since inception. 2. License and research and development services from Can-Fite: In connection with the consummation of the recapitalization transaction, the Company and Can-Fite entered into a license agreement, pursuant to which Can-Fite granted EyeFite a sole and exclusive worldwide license for the use of CF101, solely in the field of ophthalmic diseases ("CF101"). EyeFite will be obligated to make to the U.S. National Institutes of Health ("NIH"), with regard to the patents of which are included in the license to EyeFite, for as long as the license agreement between the Company and NIH remains in effect, a nonrefundable minimum annual royalty fee and potential future royalties of 4.0% to 5.5% on net sales. In addition, the Company will be obligated to make certain milestone payments ranging from $25 to $500 upon the achievement of various development milestones for each indication. EyeFite will also be required to make payments of 20% of sublicensing revenues, excluding royalties and net of the required milestone payments. During 2014 and 2015, the Company did not reach any milestone or generate revenue that would trigger additional payments to Can-Fite. As of September 30, 2015 the aggregate amount accrued for these milestones payment is $175. In addition, following the closing of the recapitalization transaction, Can-Fite, OphthaliX and EyeFite entered into a service agreement (the "Service Agreement"). Pursuant to the terms of the Service Agreement, Can-Fite will manage the research and development activities relating to pre-clinical and clinical studies for the development of the ophthalmic indications of CF101. In consideration for Can-Fite's services, EyeFite will pay to Can-Fite a service fee (consisting of all expenses and costs incurred by Can-Fite plus 15%). In addition, the Company is committed to future additional payments equal to 2.5% of any and all proceeds received by EyeFite relating to the activities regarding the drug (the "Additional Payment"). According to the Service Agreement, Can-Fite will have the right, at any time until November 21, 2016, to convert the Additional Payment into an additional 480,022 shares of Common Stock of the Company for total consideration of $2,471 (subject to adjustment in certain circumstances - See also Note 6 to the consolidated financial statements as of December 31, 2014). c. Share Purchase Agreement: On June 18, 2015, the Company entered into a Share Purchase Agreement with Improved Vision Systems (I.V.S) Ltd (“IVS”), an Israeli company and its shareholders (the “Sellers”). Subsequently, on August 25, 2015, the Share Purchase Agreement was amended (such Share Purchase Agreement, as amended, the “Agreement”). The agreement closing is pending the fulfillment of certain criteria, as further describe below. Upon the terms and subject to the conditions further described in the Agreement, the Company will acquire IVS from the Sellers through the transfer to the Company of all issued and outstanding ordinary shares of IVS in exchange for (i) the issuance by the Company of an aggregate of 2,920,748 shares of common stock of the Company to the Sellers, (ii) the issuance by the Company of options to purchase an aggregate of 303,174 shares of Common stock of the Company to holders of commitments to be granted options to purchase ordinary shares of IVS (the “Option Holders”), and (iii) the issuance by the Company of an aggregate of 2,219,771 shares of common stock of the Company to the Sellers and options to purchase 230,411 shares of common stock of the Company to the Option Holders upon the fulfillment of certain milestones (collectively, the "Milestone Securities"). The Milestone Securities shall be issued as follows: (i) 1,289,569 Milestone Securities shall be issued upon successful completion of a human clinical study of the first application of the Company’s eye tracking product and (ii) 1,160,613 Milestone Securities shall be issued upon the first commercial sale of the Company’s eye tracking product. The Company has agreed to file a registration statement registering the resale of the Company’s common stock issuable under the Agreement at such times and covering such amounts of shares as set forth in the Agreement. In addition to customary closing conditions, the initial closing is subject to, among other things, the following: (i) the Sellers shall have obtained a ruling from the Israeli Tax Authority, and (ii) completion of a fundraising by the Company in an amount no less than $3,000. If the initial closing does not take place prior to October 30, 2015, then the Agreement shall automatically terminate, unless otherwise agreed to in writing between the Company, IVS and its shareholder. d. The Company devotes most of its efforts toward research and development activities. As of September 30, 2015, the Company does not have sufficient capital resources to conduct its research and development activities until commercialization of the underlying products. The Company's inability to raise funds to conduct its research and development activities will have a severe negative impact on its ability to remain a viable company. The Company is addressing its liquidity issues by implementing initiatives to raise additional funds as well as other measures that will allow it to cover its anticipated budget deficit. Such initiatives include a plan to monetize part or all of the Company's investment in Can-Fite's ordinary shares. In addition, in February 2013 Can-Fite issued to the Company a formal letter, which has been updated periodically (most recently in August 2015), stating that Can-Fite agrees to defer payments owing to it under the Services Agreement from January 31, 2013 for the performance of the clinical trials of CF101 in ophthalmic indications until the completion of fundraising by the Company sufficient to cover such deferred payments. In addition, in August 2015, Can-Fite issued a financial support letter pursuant to which it committed to cover any shortfall in the costs and expenses of operations of the Company which are in excess of the Company's available cash to finance its operations, including cash generated from any future sale of Can-Fite shares held by the Company. Both letters remain in effect for a period of at least 14 months from August 2015 and any related balance bears interest at a rate of 3% per annum. As of September 30, 2015, the deferred payments to Can-Fite totaled $3,304. There are no assurances that the Company will be successful in obtaining an adequate level of financing needed for its long-term research and development activities. If the Company will not have sufficient liquidity resources, the Company may not be able to continue the development of all of its products or may be required to delay part of the development programs. The Company's inability to raise funds to conduct its research and development activities will have a severe negative impact on its ability to remain a viable company. Liquidity resources, as of September 30, 2015, together with the Parent company support letters described above, will be sufficient to maintain the Company's operations for at least 12 months. |
| Unaudited Condensed Financial Statements | 9 Months Ended |
| Sep. 30, 2015 | |
| Unaudited Condensed Financial Statements [Abstract] | |
| UNAUDITED CONDENSED FINANCIAL STATEMENTS | NOTE 2:- UNAUDITED CONDENSED FINANCIAL STATEMENTS The unaudited Condensed Consolidated Financial Statements of OphthaliX Inc. have been prepared in accordance with U.S. generally accepted accounting principles ("U.S. GAAP") for interim financial information and the rules and regulations of the U.S. Securities and Exchange Commission ("SEC"). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The condensed consolidated balance sheets as of September 30, 2015, included herein were derived from the audited consolidated financial statements for the year ended December 31, 2014. In the opinion of management, all adjustments, including normal recurring accruals, considered necessary for a fair presentation have been included. The results of operations for the three months ended September 30, 2015, are not necessarily indicative of the results that may be expected for the year ending December 31, 2015, or any future period. The information included in this interim report should be read in conjunction with "Management's Discussion and Analysis of Financial Condition and Results of Operations," "Risk Factors," "Quantitative and Qualitative Disclosures About Market Risk," and the consolidated financial statements and footnotes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2014. The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could differ materially from those estimates under different assumptions or conditions. |
| Fair Value Measurements | 9 Months Ended |
| Sep. 30, 2015 | |
| Fair Value Measurements [Abstract] | |
| FAIR VALUE MEASUREMENTS | NOTE 3:- FAIR VALUE MEASUREMENTS The significant accounting policies applied in the annual financial statements of the Company as of December 31, 2014 are applied consistently in these condensed financial statements. For further information, refer to the consolidated financial statements as of December 31, 2014. The Company considers an active market to be one in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis, and views an inactive market as one in which there are few transactions for the asset or liability, the prices are not current, or price quotations vary substantially either over time or among market makers. Since the quoted market value of the Company’s Common Stock was based on a sporadically traded stock with little volume, the Company's management determined the Company's stock price fair value based on ASC 820 Fair Value Measurement using the income approach assisted by a third party specialist. Consequently, the derivatives are classified within Level 3 because they are valued using valuation techniques. The fair value of the Derivative was determined using the binomial option-pricing model. This model requires a number of assumptions, of which most significant are the expected stock price volatility and the expected term. The fair value of the Derivative as of September 30, 2015 and December 31, 2014 was immaterial. The Company's investment in Parent Company ordinary shares is measured in accordance with ASC 820, based on the Parent Company's ordinary shares fair value as quoted in the Tel Aviv Stock Exchange. These securities are classified as available-for-sale securities carried at fair value, with unrealized gains and losses reported as a separate component of shareholders' equity under accumulated other comprehensive loss (income) in the condensed consolidated balance sheets. The assets are classified within Level 1 on the fair value hierarchy. The following table provides information by value level for financial assets and liabilities that are measured at fair value, as defined by ASC 820, on a recurring basis as of September 30, 2015 and December 31, 2014. September 30, 2015 Fair value measurements Description Fair Value Level 1 Level 2 Level 3(1) Investment in Parent Company $ 962 $ 962 $ - $ - Derivative related to Service Agreement *) - - - *) - Total Financial Assets, net $ 962 $ 962 $ - $ *) - *) Represents an amount lower than $1 December 31, 2014 Fair value measurements Description Fair Value Level 1 Level 2 Level 3(1) Investment in Parent company $ 794 $ 794 $ - $ - Derivative related to Service Agreement *) - - - *) - Total Financial Assets, net $ 794 $ 794 $ - $ *) - *) Represents an amount lower than $1 (1) Fair value measurements using significant unobservable inputs During the nine months ended September 30, 2015 the changes in Level 3 instruments measured on a recurring basis was immaterial. |
| Equity | 9 Months Ended |
| Sep. 30, 2015 | |
| Equity [Abstract] | |
| EQUITY | NOTE 4:- EQUITY The following table summarizes the activity of stock options: Shares Subject to Options Outstanding Description Number of Shares Weighted Average Exercise Price Weighted- Average Remaining Contractual Term Aggregate Intrinsic Value (1) Outstanding as of January 1, 2015 117,500 7.96 7.8 $ - Granted - - - - Expired - - - - Forfeited/cancelled - - - - Outstanding as of September 30, 2015 117,500 7.96 7.15 $ - Exercisable as of September 30, 2015 102,812 8.10 7.06 - Vested and expected to be vested 117,500 7.96 7.15 $ - (1) The aggregate intrinsic value is calculated as the difference between the exercise price of the stock options and the closing price of the shares of the Company’s Common Stock of $ 0.99 as of September 30, 2015. As of September 30, 2015, there was $7 of unrecognized stock-based compensation expense all of which is related to stock options. This unrecognized compensation expense, expected to be recognized over a weighted-average period of approximately 0.5 years. |
| Fair Value Measurements (Tables) | 9 Months Ended |
| Sep. 30, 2015 | |
| Fair Value Measurements [Abstract] | |
| Summary of financial assets and liabilities measured at fair value on recurring basis | September 30, 2015 Fair value measurements Description Fair Value Level 1 Level 2 Level 3(1) Investment in Parent Company $ 962 $ 962 $ - $ - Derivative related to Service Agreement *) - - - *) - Total Financial Assets, net $ 962 $ 962 $ - $ *) - *) Represents an amount lower than $1 December 31, 2014 Fair value measurements Description Fair Value Level 1 Level 2 Level 3(1) Investment in Parent company $ 794 $ 794 $ - $ - Derivative related to Service Agreement *) - - - *) - Total Financial Assets, net $ 794 $ 794 $ - $ *) - *) Represents an amount lower than $1 |
| Equity (Tables) | 9 Months Ended |
| Sep. 30, 2015 | |
| Equity [Abstract] | |
| Schedule of stock options activity | Shares Subject to Options Outstanding Description Number of Shares Weighted Average Exercise Price Weighted- Average Remaining Contractual Term Aggregate Intrinsic Value (1) Outstanding as of January 1, 2015 117,500 7.96 7.8 $ - Granted - - - - Expired - - - - Forfeited/cancelled - - - - Outstanding as of September 30, 2015 117,500 7.96 7.15 $ - Exercisable as of September 30, 2015 102,812 8.10 7.06 - Vested and expected to be vested 117,500 7.96 7.15 $ - (1) The aggregate intrinsic value is calculated as the difference between the exercise price of the stock options and the closing price of the shares of the Company’s Common Stock of $ 0.99 as of September 30, 2015. |
| General (Details) - USD ($) $ / shares in Units, $ in Thousands | 1 Months Ended | 9 Months Ended | 12 Months Ended | ||
| Jun. 18, 2015 | Jun. 17, 2013 | Nov. 21, 2011 | Sep. 30, 2015 | Dec. 31, 2014 | |
| General [Textual] | |||||
| Common Stock, par value | $ 0.001 | $ 0.001 | |||
| Accrued for milestones payment | $ 175 | ||||
| License agreement terms | license agreement between the Company and NIH remains in effect, a nonrefundable minimum annual royalty fee and potential future royalties of 4.0% to 5.5% on net sales. | ||||
| Percentage of sublicensing revenues | 0.00405% | ||||
| Percentage of expenses | 15.00% | ||||
| Future additional payments percentage | 2.50% | ||||
| Bearing interest rate per annum | 3.00% | ||||
| Fund raised by meet the shareholder requirements | $ 3,000 | ||||
| Deferred payments | 3,304 | $ 2,457 | |||
| Maximum [Member] | |||||
| General [Textual] | |||||
| Payment for milestone | 500 | ||||
| Minimum [Member] | |||||
| General [Textual] | |||||
| Payment for milestone | $ 25 | ||||
| Eye-Fite Ltd [Member] | |||||
| General [Textual] | |||||
| Shares issued for acquired outstanding shares | 8,000,000 | ||||
| Common Stock, par value | $ 0.001 | ||||
| Percentage of sublicensing revenues | 20.00% | ||||
| Can-Fite [Member] | |||||
| General [Textual] | |||||
| Shares issued, price per share | $ 5.148 | ||||
| Ordinary shares received | 714,922 | ||||
| Percentage of issued and outstanding share capital on Closing Date | 7.00% | ||||
| Total consideration received for sale of stock | $ 511 | $ 2,471 | |||
| Ordinary shares held | 268,095 | 446,827 | |||
| Percentage of issued and outstanding share capital | 1.60% | ||||
| Warrants exercisable period | 5 years | ||||
| Exercise price of the warrants | $ 7.74 | ||||
| Common Stock converted to additional payment | 480,022 | 480,022 | |||
| Option Holders [Member] | |||||
| General [Textual] | |||||
| Common stock shares issued | 2,920,748 | ||||
| Options to purchase shares of common stock | 303,174 | ||||
| Milestone Securities [Member] | |||||
| General [Textual] | |||||
| Common stock shares issued | 2,219,771 | ||||
| Options to purchase shares of common stock | 230,411 | ||||
| Share based arrangement for issuing shares | (i) 1,289,569 Milestone Securities shall be issued upon successful completion of a human clinical study of the first application of the Company's eye tracking product and (ii) 1,160,613 Milestone Securities shall be issued upon the first commercial sale of the Company's eye tracking product. | ||||
| Fair Value Measurements (Details) - Recurring [Member] - USD ($) $ in Thousands | Sep. 30, 2015 | Dec. 31, 2014 | |
| Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | |||
| Investment in Parent Company | $ 962 | $ 794 | |
| Derivative related to Service Agreement | [1] | ||
| Total Financial Assets, net | $ 962 | $ 794 | |
| Level 1 [Member] | |||
| Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | |||
| Investment in Parent Company | $ 962 | $ 794 | |
| Derivative related to Service Agreement | |||
| Total Financial Assets, net | $ 962 | $ 794 | |
| Level 2 [Member] | |||
| Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | |||
| Investment in Parent Company | |||
| Derivative related to Service Agreement | |||
| Total Financial Assets, net | |||
| Level 3 [Member] | |||
| Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | |||
| Investment in Parent Company | |||
| Derivative related to Service Agreement | [1] | ||
| Total Financial Assets, net | |||
| [1] | Represents an amount lower than $1 | ||
| Equity (Details) - Employee Stock Option [Member] | 9 Months Ended | |
| Sep. 30, 2015USD ($)$ / sharesshares | ||
| Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] | ||
| Number of Shares, Outstanding | shares | 117,500 | |
| Number of shares, Granted | shares | ||
| Number of shares, Expired | shares | ||
| Number of shares, Forfeited/cancelled | shares | ||
| Number of Shares, Outstanding | shares | 117,500 | |
| Number of Shares, Exercisable | shares | 102,812 | |
| Number of Shares, Vested and expected to be vested | shares | 117,500 | |
| Weighted Average Exercise Price, Outstanding | $ 7.96 | |
| Weighted Average Exercise Price, Granted | ||
| Weighted Average Exercise Price, Expired | ||
| Weighted Average Exercise Price, Forfeited/cancelled | ||
| Weighted Average Exercise Price, Outstanding | $ 7.96 | |
| Weighted Average Exercise Price, Exercisable | 8.10 | |
| Weighted Average Exercise Price, Vested and expected to be vested | $ 7.96 | |
| Weighted Average Remaining Contractual Term, Outstanding (in years) | 7 years 9 months 18 days | |
| Weighted Average Remaining Contractual Term, Outstanding (in years) | 7 years 1 month 24 days | |
| Weighted Average Remaining Contractual Term, Exercisable (in years) | 7 years 22 days | |
| Weighted Average Remaining Contractual Term, Vested and expected to be vested (in years) | 7 years 1 month 24 days | |
| Aggregate Intrinsic Value, Outstanding | $ | [1] | |
| Aggregate Intrinsic Value, Granted | [1] | |
| Aggregate Intrinsic Value, Expired | [1] | |
| Aggregate Intrinsic Value, Forfeited/cancelled | $ | [1] | |
| Aggregate Intrinsic Value, Outstanding | $ | [1] | |
| Aggregate Intrinsic Value, Exercisable | $ | [1] | |
| Aggregate Intrinsic Value, Vested and expected to be vested | $ | [1] | |
| [1] | The aggregate intrinsic value is calculated as the difference between the exercise price of the stock options and the closing price of the shares of the Company's Common Stock of $ 0.99 as of September 30, 2015. | |
| Equity (Details Textual) $ / shares in Units, $ in Thousands | 9 Months Ended |
| Sep. 30, 2015USD ($)$ / shares | |
| Equity (Textual) | |
| Closing price of the shares | $ / shares | $ 0.99 |
| Unrecognized stock-based compensation expense related to stock options | $ 7 |
| Unrecognised compensation expense, expected to recognized weighted average period | 6 months |
